Mind + Muscle

technical minds + legal muscle


dig deep

ImmunoGen Cancer Patent Still Valid After Phigenix's Dispute

  • 10.29.15
  • Eldora L. Ellison, Ph.D.
  • Bloomberg BNA

Eldora Ellison, Ph.D., is quoted in Bloomberg BNA's, "Immunogen Cancer Patent Still Valid After Phigenix's Dispute," discussing the Patent Trial and Appeal Board's (PTAB) final written decision to uphold the validity of ImmunoGen, Inc.'s U.S. Patent Number 8,337,856 B2 for its breast-cancer treatment drug Kadcyla.

Dr. Ellison remarked, "Our team was very pleased that the PTAB upheld this patent covering Kadcyla, which is an innovative drug that has changed the lives of breast cancer patients."

Sterne Kessler represented ImmunoGen in this matter. The team is led by Dr. Ellison and includes, Eric Steffe, Olga Partington, Ph.D.Cynthia DeRenzo, Ph.D.David Roadcap, Ph.D., and Christopher Gallo, Ph.D.

Related People

Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.